Alnylam Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

08.01.24	Alnylam Pharma Announces Preliminary 2023 Global Net Product Revenue (RTTNews)
13.12.23	Alnylam Pharma Announces Product And Pipeline Goals (RTTNews)
02.11.23	Alnylam Pharmaceuticals Inc. Q3 Earnings Summary (RTTNews)
01.11.23	Ausblick: Alnylam Pharmaceuticals präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net)
25.10.23	Alnylam Pharma Reports Additional Positive Interim Phase 1 Results For Alzheimer's Disease Treatment (RTTNews)
09.10.23	Alnylam Pharma Decides Not To Pursue Expanded Indication For Patisiran In The U.S. (RTTNews)
13.09.23	Alnylam Pharmaceuticals: FDA Committee To Review SNDA For Patisiran; Trading Halted (RTTNews)
07.09.23	Alnylam: KARDIA-1 Phase 2 Dose-Ranging Study Of Zilebesiran Meets Primary Endpoint (RTTNews)
31.08.23	Biotech Stocks Facing FDA Decision In September 2023 (RTTNews)
26.08.23	Alnylam Pharma To Appeal U.S. Court Ruling On Two Patents Asserted Against Moderna (RTTNews)
03.08.23	Alnylam Pharmaceuticals Inc. Q2 Loss Decreases, but misses estimates (RTTNews)
02.08.23	Ausblick: Alnylam Pharmaceuticals zieht Bilanz zum abgelaufenen Quartal (finanzen.net)
24.07.23	Alnylam, Roche Partner To Co-Develop, Co-Commercialize Zilebesiran (RTTNews)
17.07.23	Alnylam Presents ALN-APP's Updated Positive Interim Phase 1 Results In Alzheimer's Disease, CAA (RTTNews)
30.06.23	Alnylam's Onpattro To Be Reviewed By FDA Panel In September (RTTNews)
04.05.23	Alnylam Pharmaceuticals Inc. Q1 Loss Decreases, beats estimates (RTTNews)
03.05.23	Ausblick: Alnylam Pharmaceuticals mit Zahlen zum abgelaufenen Quartal (finanzen.net)
09.03.23	Alnylam Pharma To Extend Its Existing Relationship With Medison (RTTNews)
09.03.23	Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics (PR Newswire)
23.02.23	Alnylam Pharmaceuticals Inc. Q4 Loss Decreases, beats estimates (RTTNews)
22.02.23	Ausblick: Alnylam Pharmaceuticals zieht Bilanz zum abgelaufenen Quartal (finanzen.net)
21.02.23	Alnylam Pharma : FDA Accepts SNDA For Patisiran For Treatment Of Cardiomyopathy Of ATTR Amyloidosis (RTTNews)
08.02.23	Erste Schätzungen: Alnylam Pharmaceuticals mit Zahlen zum abgelaufenen Quartal (finanzen.net)
09.01.23	Alnylam Announces Preliminary Q4 Global Net Product Revenues (RTTNews)
21.12.22	Alnylam Pharma Submits CTA Application For ALN-KHK For Treatment Of Type 2 Diabetes (RTTNews)
28.10.22	ALNY Reiterates Guidance, TVTX Loss Widens, DXCM Paints Rosy Outlook (RTTNews)
27.10.22	Alnylam Pharmaceuticals Inc. Q3 Loss Increases, but beats estimates (RTTNews)
07.10.22	Alnylam's Oxlumo Indicated For Treatment Of PH1 To Lower Urinary And Plasma Oxalate Levels (RTTNews)
30.09.22	Biotech Stocks Facing FDA Decision In October 2022 (RTTNews)
20.09.22	Alnylam's AMVUTTRA Gets Approval In Europe To Treat Hereditary Transthyretin-mediated Amyloidosis (RTTNews)
15.09.22	Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers (PR Newswire)
08.09.22	Alnylam Presents Positive Results From Phase 3 Study Of Patisiran In ATTR Amyloidosis (RTTNews)
29.08.22	Alnylam: Additional Data Shows Favorable Effects Of Cemdisiran On Different Measures Of proteinuria (RTTNews)
03.08.22	Alnylam : Phase 3 Study Of Patisiran In ATTR Amyloidosis With Cardiomyopathy Meets Main Goal (RTTNews)
29.07.22	Alnylam Q2 Loss Widens, SGEN Boosts Revenue Outlook, NVCR To Report LUNAR Study Data In Q1 (RTTNews)
28.07.22	Alnylam Pharmaceuticals Net Loss Widens In Q2 (RTTNews)
28.07.22	Alnylam Pharmaceuticals Inc. Q2 Loss Decreases, but misses estimates (RTTNews)
27.07.22	Ausblick: Alnylam Pharmaceuticals stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net)
09.06.22	Alnylam Pharma Reports Positive Topline Results From Phase 2 Study Of Cemdisiran (RTTNews)
18.05.22	Alnylam Pharma Says Canada Authorizes OXLUMO For Treatment Of Primary Hyperoxaluria Type 1 (RTTNews)
29.04.22	ACCD Guides Q1 Well Below Analysts' Estimates, ALNY Cuts Outlook, NVCR Braces For Busy Year (RTTNews)
28.04.22	Alnylam Pharmaceuticals Inc. Q1 Loss Decreases, beats estimates (RTTNews)
27.04.22	Ausblick: Alnylam Pharmaceuticals legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net)
04.04.22	Alnylam Pharma: FDA Extends Review Timeline Of NDA For Vutrisiran - Quick Facts (RTTNews)
28.03.22	Biotech Stocks Facing FDA Decision In April 2022 (RTTNews)
17.03.22	Alnylam Files Patent Infringement Suits Against Pfizer And Moderna On COVID-19 Vaccines (RTTNews)
01.03.22	Alnylam : FDA Accepts OXLUMO SNDA For Treatment Of Advanced Primary Hyperoxaluria Type 1 (RTTNews)
10.02.22	Alnylam Pharma Provides 2022 Combined Net Product Revenue Guidance - Quick Facts (RTTNews)
10.02.22	Alnylam Pharmaceuticals Inc. Q4 Earnings Summary (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Alnylam Pharmaceuticals Inc.

Aktien Top/Flop

Meistgelesene Nachrichten